Norge -
norsk -
Statens legemiddelverk
tecfidera 240 mg
2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg
Norge -
norsk -
Statens legemiddelverk
tecfidera 240 mg
orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg
Norge -
norsk -
Statens legemiddelverk
tecfidera 120 mg
orifarm as - dimetylfumarat - enterokapsel, hard - 120 mg
Norge -
norsk -
Statens legemiddelverk
cymbalta 30 mg
2care4 aps - duloksetinhydroklorid - enterokapsel, hard - 30 mg
Norge -
norsk -
Statens legemiddelverk
cymbalta 60 mg
2care4 aps - duloksetinhydroklorid - enterokapsel, hard - 60 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.